QLOSI Drug Patent Profile
✉ Email this page to a colleague
When do Qlosi patents expire, and what generic alternatives are available?
Qlosi is a drug marketed by Orasis Pharms and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-four patent family members in fourteen countries.
The generic ingredient in QLOSI is pilocarpine hydrochloride. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Qlosi
A generic version of QLOSI was approved as pilocarpine hydrochloride by PADAGIS US on November 16th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QLOSI?
- What are the global sales for QLOSI?
- What is Average Wholesale Price for QLOSI?
Summary for QLOSI
| International Patents: | 24 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in QLOSI? | QLOSI excipients list |
| DailyMed Link: | QLOSI at DailyMed |
Pharmacology for QLOSI
| Drug Class | Cholinergic Receptor Agonist |
| Mechanism of Action | Cholinergic Agonists Cholinergic Muscarinic Agonists |
US Patents and Regulatory Information for QLOSI
QLOSI is protected by four US patents and one FDA Regulatory Exclusivity.
Patents protecting QLOSI
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA
FDA Regulatory Exclusivity protecting QLOSI
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QLOSI
See the table below for patents covering QLOSI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 4190328 | ⤷ Sign Up | |
| China | 116726006 | 眼科药物组合物及其相关用途 (Ophthalmic pharmaceutical compositions and uses related thereto) | ⤷ Sign Up |
| Israel | 297367 | תכשירי רוקחות עיניים ושימושים הקשורים אליהם (Ophthalmic pharmaceutical compositions and uses relating thereto) | ⤷ Sign Up |
| Russian Federation | 2019107585 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
